ODN D-SL03 is a C class CpG oligonucleotides , can induce stimulate PBMCs to produce high level of IFN-α . ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' In Vitro ODN D-SL03 (0-3 μg/mL; 36 h) significantly induces IFN-α production in PBMCs at 0.19 μg/mL. ODN D-SL03 (3 μg/mL; 18 or 36 h) activates immune cells including B, NK, T and monocyte cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo ODN D-SL03 (25 μg per mouse; Peritumoral injection) induces significant inhibition of tumor growth . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female BALB/c mice (6-8 weeks; inoculated with 5×10 5 EMT6 cells) Dosage: 25 μg per mouse Administration: Peritumoral injection, six times in one-day interval, for 0-100 days Result: Induced significant inhibition of tumor growth. Form:Solid IC50& Target:IFN-α